AttributesValues
Author
Bibliographic Citation
  • ChauvinCamille, LevillayerLaurine, RoumierMathilde, NiellyHubert, RothClaude, KarnamAnupama, BonamSrinivasa Reddy, BourgaritAnne, DubostClément, BousquetAurore, Le BurelSébastien, MestiriRaphaële, SeneDamien, GallandJoris, VasseMarc, GrohMatthieu, Le MarchandMathilde, Vassord-DangCamille, GautierJean-François, Pham-ThiNhan, VernyChristiane, PitardBruno, PlanchaisCyril, MouquetHugo, PaulRichard, Simon-LoriereEtienne, BayryJagadeesh, GilardinLaurent, SakuntabhaiAnavaj . Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants . iScience, 2023, 26 (3), pp.106124 . ⟨10.1016/j.isci.2023.106124⟩
  • ChauvinCamille, LevillayerLaurine, RoumierMathilde, NiellyHubert, RothClaude, KarnamAnupama, BonamSrinivasa Reddy, BourgaritAnne, DubostClément, BousquetAurore, Le BurelSébastien, MestiriRaphaële, SeneDamien, GallandJoris, VasseMarc, GrohMatthieu, Le MarchandMathilde, Vassord-DangCamille, GautierJean-François, Pham-ThiNhan, VernyChristiane, PitardBruno, PlanchaisCyril, MouquetHugo, PaulRichard, Simon-LoriereEtienne, BayryJagadeesh, GilardinLaurent, SakuntabhaiAnavaj. Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. iScience, 2023, 26 (3), pp.106124. ⟨10.1016/j.isci.2023.106124⟩
Title
  • Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
dc:date
  • 2023
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software